Literature DB >> 2996417

Leukotrienes increase blood-brain barrier permeability following intraparenchymal injections in rats.

K L Black, J T Hoff.   

Abstract

To examine whether leukotrienes could increase blood-brain barrier permeability, rats were anesthetized and injected intravenously with Evans blue. Ten microliters of vehicle, of leukotrienes B4, C4, or E4, or of arachidonic acid was injected over 1 hour directly into the brain parenchyma. The percentage of the total surface area of Evans blue extravasation in a coronal section of brain centered on the injection site was then determined as an estimate of blood-brain barrier permeability. Leukotrienes B4, C4, and E4, and arachidonic acid all increased blood-brain barrier permeability, but this effect was lost when the total dose was reduced to 20 ng. Increased blood-brain barrier permeability induced by arachidonic acid could be prevented by pretreatment with the lipoxygenase inhibitor BW755C, but not with indomethacin. Leukotrienes may play a role in the development of increased blood-brain barrier permeability after cerebral injury.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996417     DOI: 10.1002/ana.410180313

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  Suppression of experimental autoimmune encephalomyelitis by a new specific leukotriene biosynthesis inhibitor.

Authors:  I S Neu; J Mallinger; A Wildfeuer; L Mehlber
Journal:  J Neurol       Date:  1992-10       Impact factor: 4.849

Review 2.  Mechanisms of blood-brain barrier breakdown.

Authors:  J Greenwood
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

Review 3.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

4.  The contribution of arachidonic acid to the aetiology and pathophysiology of focal brain oedema; studies using an infusion oedema model.

Authors:  I R Whittle; I R Piper; J D Miller
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

5.  Permeability and vasomotor response of cerebral vessels during exposure to arachidonic acid.

Authors:  A Unterberg; M Wahl; F Hammersen; A Baethmann
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

6.  Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds.

Authors:  Y Kashida; M Kato
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

7.  Clearance and metabolism of arachidonic acid by C6 glioma cells and astrocytes.

Authors:  F Staub; A Winkler; J Peters; U Goerke; O Kempski; A Baethmann
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

8.  Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family.

Authors:  R J Boado; W M Pardridge; H V Vinters; K L Black
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

9.  Cerebromicrovascular endothelial permeability. In-vitro studies.

Authors:  O Kempski; A Villacara; M Spatz; R F Dodson; C Corn; N Merkel; J Bembry
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.

Authors:  C C Chio; S J Lin; M T Lin
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.